卵巢颗粒细胞瘤诊治进展

doi:10.12280/gjfckx.20220471

摘要/Abstract

摘要：

卵巢颗粒细胞瘤（ovarian granulosa cell tumor，OGCT）起源于性索间质，相对罕见，约占卵巢肿瘤的2%~5%。按照组织病理学特点分为成人型颗粒细胞瘤（adult granulosa cell tumor，AGCT）和幼年型颗粒细胞瘤（juvenile granulosa cell tumor，JGCT）。因具有激素分泌功能临床上常表现为雌激素刺激症状。翼状螺旋/叉头转录因子2（forkhead transcription factor2，FOXL2）基因c.402C→G突变是AGCT的重要致病因素和分子诊断标记。手术是OGCT的首选治疗方法。临床分期是影响患者预后最重要的因素。抑制素β、抗苗勒管激素可作为诊断OGCT的血清学标志物。OGCT总体预后较好，因具有远期复发的特点，应坚持长期随访。

关键词: 卵巢肿瘤, 颗粒细胞瘤, 叉头转录因子类, 治疗

Abstract:

Ovarian granulosa cell tumor (OGCT) is a rare neoplasia of sex-cord stromal origin and accounts for 2%-5% of ovarian tumors. It can be divided into adult granulosa cell tumor (AGCT) and juvenile granulosa cell tumor (JGCT) according to the histopathological characteristics. Due to its secretion function, it often presents estrogen stimulation symptom. Mutation of FOXL2 gene c.402C→G is the most important pathogenic factor in AGCT and a molecular diagnostic marker. Surgery is the first choice for OGCT. The most important factor affecting the prognosis of patients is clinical stage. Inhibin β and AMH can be used as serological markers in diagnosis and detection of OGCT. OGCT generally has a favorable prognosis. Due to the characteristics of long-term recurrence, long-term follow-up should be insisted.

Key words: Ovarian neoplasms, Granular cell tumor, Forkhead transcription factors, Therapy

周丽, 曲芃芃. 卵巢颗粒细胞瘤诊治进展[J]. 国际妇产科学杂志, 2022, 49(6): 630-634.

ZHOU Li, QU Peng-peng. Advances in Diagnosis and Treatment of Ovarian Granulosa Cell Tumor[J]. Journal of International Obstetrics and Gynecology, 2022, 49(6): 630-634.

参考文献 31

[1]	Li J, Bao R, Peng S, et al. The molecular mechanism of ovarian granulosa cell tumors[J]. J Ovarian Res, 2018, 11(1):13. doi: 10.1186/s13048-018-0384-1. doi: 10.1186/s13048-018-0384-1 pmid: 29409506
[2]	Bryk S, Pukkala E, Martinsen JI, et al. Incidence and occupational variation of ovarian granulosa cell tumours in Finland, Iceland, Norway and Sweden during 1953-2012: a longitudinal cohort study[J]. BJOG, 2017, 124(1):143-149. doi: 10.1111/1471-0528.13949. doi: 10.1111/1471-0528.13949
[3]	Shah SP, Köbel M, Senz J, et al. Mutation of FOXL2 in granulosa-cell tumors of the ovary[J]. N Engl J Med, 2009, 360(26):2719-2729. doi: 10.1056/NEJMoa0902542. doi: 10.1056/NEJMoa0902542
[4]	Fuller PJ, Leung D, Chu S. Genetics and genomics of ovarian sex cord-stromal tumors[J]. Clin Genet, 2017, 91(2):285-291. doi: 10.1111/ cge.12917. doi: 10.1111/cge.12917 pmid: 27813081
[5]	Färkkilä A, Andersson N, Bützow R, et al. HER2 and GATA4 are new prognostic factors for early-stage ovarian granulosa cell tumor-a long-term follow-up study[J]. Cancer Med, 2014, 3(3):526-536. doi: 10.1002/cam4.230. doi: 10.1002/cam4.230
[6]	Pilsworth JA, Cochrane DR, Neilson SJ, et al. Adult-type granulosa cell tumor of the ovary: a FOXL2-centric disease[J]. J Pathol Clin Res, 2021, 7(3):243-252. doi: 10.1002/cjp2.198. doi: 10.1002/cjp2.198
[7]	Alexiadis M, Rowley SM, Chu S, et al. Mutational Landscape of Ovarian Adult Granulosa Cell Tumors from Whole Exome and Targeted TERT Promoter Sequencing[J]. Mol Cancer Res, 2019, 17(1):177-185. doi: 10.1158/1541-7786.MCR-18-0359. doi: 10.1158/1541-7786.MCR-18-0359 pmid: 30166312
[8]	Parikshaa G, Ariba Z, Pranab D, et al. Juvenile granulosa cell tumor of the ovary: A comprehensive clinicopathologic analysis of 15 cases[J]. Ann Diagn Pathol, 2021, 52:151721. doi: 10.1016/j.anndiagpath.2021.151721. doi: 10.1016/j.anndiagpath.2021.151721
[9]	Van den Berghe I, Dal Cin P, De Groef K, et al. Monosomy 22 and trisomy 14 may be early events in the tumorigenesis of adult granulosa cell tumor[J]. Cancer Genet Cytogenet, 1999, 112(1):46-48. doi: 10.1016/s0165-4608(98)00249-0. doi: 10.1016/s0165-4608(98)00249-0
[10]	Caburet S, Anttonen M, Todeschini AL, et al. Combined comparative genomic hybridization and transcriptomic analyses of ovarian granulosa cell tumors point to novel candidate driver genes[J]. BMC Cancer, 2015, 15:251. doi: 10.1186/s12885-015-1283-0. doi: 10.1186/s12885-015-1283-0 pmid: 25884336
[11]	Littrell LA, Inwards CY, Hazard FK, et al. Juvenile granulosa cell tumor associated with Ollier disease[J]. Skeletal Radiol, 2022 Mar 16. doi: 10.1007/s00256-022-04033-5. Epub ahead of print. doi: 10.1007/s00256-022-04033-5
[12]	Hachi H, Othmany A, Douayri A, et al. Association of ovarian juvenile granulosa cell tumor with Maffucci′s syndrome[J]. Gynecol Obstet Fertil, 2002, 30(9):692-695. doi: 10.1016/s1297-9589(02)00416-2. doi: 10.1016/s1297-9589(02)00416-2
[13]	Inada Y, Nakai G, Yamamoto K, et al. Rapidly growing juvenile granulosa cell tumor of the ovary arising in adult: a case report and review of the literature[J]. J Ovarian Res, 2018, 11(1):100. doi: 10.1186/s13048-018-0474-0. doi: 10.1186/s13048-018-0474-0 pmid: 30547828
[14]	Matsuki M, Numoto I, Suzuki A, et al. Magnetic Resonance Imaging of Recurrent Adult Granulosa Cell Tumor of the Ovary: A Retrospective Analysis of 11 Cases[J]. J Comput Assist Tomogr, 2020, 44(6):887-892. doi: 10.1097/RCT.0000000000001096. doi: 10.1097/RCT.0000000000001096
[15]	Portuesi R, Loppini A, Mancari R, et al. Role of inhibin B in detecting recurrence of granulosa cell tumors of the ovary in postmenopausal patients[J]. Int J Gynecol Cancer, 2021, 31(6):893-898. doi: 10.1136/ijgc-2020-002205. doi: 10.1136/ijgc-2020-002205 pmid: 33893147
[16]	Hanley KZ, Mosunjac MB. Practical Review of Ovarian Sex Cord-Stromal Tumors[J]. Surg Pathol Clin, 2019, 12(2):587-620. doi: 10.1016/j.path.2019.02.005. doi: S1875-9181(19)30016-9 pmid: 31097116
[17]	Baillard P, Genestie C, Croce S, et al. Rare DICER1 and Absent FOXL2 Mutations Characterize Ovarian Juvenile Granulosa Cell Tumors[J]. Am J Surg Pathol, 2021, 45(2):223-229. doi: 10.1097/PAS.0000000000001582. doi: 10.1097/PAS.0000000000001582
[18]	Rabban JT, Karnezis AN, Devine WP. Practical roles for molecular diagnostic testing in ovarian adult granulosa cell tumour, Sertoli-Leydig cell tumour, microcystic stromal tumour and their mimics[J]. Histopathology, 2020, 76(1):11-24. doi: 10.1111/his.13978. doi: 10.1111/his.13978 pmid: 31846522
[19]	卢淮武, 吴斌, 许妙纯, 等. 《2022 NCCN卵巢癌包括输卵管癌及原发性腹膜癌临床实践指南(第1版)》解读[J]. 中国实用妇科与产科杂志, 2022, 38(3):310-318. doi:10.19538/j.fk2022030113. doi: 10.19538/j.fk2022030113
[20]	Peiretti M, Candotti G, Fais ML, et al. Comparison between laparoscopy and laparotomy in the surgical re-staging of granulosa cell tumors of the ovary[J]. Gynecol Oncol, 2020, 157(1):85-88. doi: 10.1016/j.ygyno.2019.12.040. doi: S0090-8258(19)31870-0 pmid: 31954531
[21]	Nasioudis D, Kanninen TT, Holcomb K, et al. Prevalence of lymph node metastasis and prognostic significance of lymphadenectomy in apparent early-stage malignant ovarian sex cord-stromal tumors[J]. Gynecol Oncol, 2017, 145(2):243-247. doi: 10.1016/j.ygyno.2017.03.005. doi: S0090-8258(17)30205-6 pmid: 28292524
[22]	Ebina Y, Yamagami W, Kobayashi Y, et al. Clinicopathological characteristics and prognostic factors of ovarian granulosa cell tumors: A JSGO-JSOG joint study[J]. Gynecol Oncol, 2021, 163(2):269-273. doi: 10.1016/j.ygyno.2021.08.012. doi: 10.1016/j.ygyno.2021.08.012 pmid: 34454726
[23]	Zhao D, Song Y, Zhang Y, et al. Outcomes of fertility-sparing surgery in ovarian juvenile granulosa cell tumor[J]. Int J Gynecol Cancer, 2019, 29(4):787-791. doi: 10.1136/ijgc-2018-000083. doi: 10.1136/ijgc-2018-000083 pmid: 30728165
[24]	Wang D, Cao D, Jia C, et al. Analysis of oncologic and reproductive outcomes after fertility-sparing surgery in apparent stage I adult ovarian granulosa cell tumors[J]. Gynecol Oncol, 2018, 151(2):275-281. doi: 10.1016/j.ygyno.2018.09.004. doi: S0090-8258(18)31214-9 pmid: 30219238
[25]	Wang D, Xiang Y, Wu M, et al. Is adjuvant chemotherapy beneficial for patients with FIGO stage IC adult granulosa cell tumor of the ovary?[J]. J Ovarian Res, 2018, 11(1):25. doi: 10.1186/s13048-018-0396-x. doi: 10.1186/s13048-018-0396-x pmid: 29587835
[26]	Zhao D, Zhang Y, Ou Z, et al. Characteristics and treatment results of recurrence in adult-type granulosa cell tumor of ovary[J]. J Ovarian Res, 2020, 13(1):19. doi: 10.1186/s13048-020-00619-6. doi: 10.1186/s13048-020-00619-6 pmid: 32059683
[27]	Yasukawa M, Matsuo K, Matsuzaki S, et al. Management of recurrent granulosa cell tumor of the ovary: Contemporary literature review and a proposal of hyperthermic intraperitoneal chemotherapy as novel therapeutic option[J]. J Obstet Gynaecol Res, 2021, 47(1):44-51. doi: 10.1111/jog.14494. doi: 10.1111/jog.14494
[28]	Mills AM, Chinn Z, Rauh LA, et al. Emerging biomarkers in ovarian granulosa cell tumors[J]. Int J Gynecol Cancer, 2019, 29(3):560-565. doi: 10.1136/ijgc-2018-000065. doi: 10.1136/ijgc-2018-000065 pmid: 30833441
[29]	Poddubskaya EV, Baranova MP, Allina DO, et al. Personalized prescription of imatinib in recurrent granulosa cell tumor of the ovary: case report[J]. Cold Spring Harb Mol Case Stud, 2019, 5(2):a003434. doi: 10.1101/mcs.a003434. doi: 10.1101/mcs.a003434
[30]	Pierini S, Tanyi JL, Simpkins F, et al. Ovarian granulosa cell tumor characterization identifies FOXL2 as an immunotherapeutic target[J]. JCI Insight, 2020, 5(16):e136773. doi: 10.1172/jci.insight.136773. doi: 10.1172/jci.insight.136773
[31]	Hillmanab RT, Lind DI, Lawson B, et al. Prevalence of predictive biomarkers in a large cohort of molecularly defined adult-type ovarian granulosa cell tumors[J]. Gynecol Oncol, 2021, 162(3):728-734. doi: 10.1016/j.ygyno.2021.06.024. doi: 10.1016/j.ygyno.2021.06.024 pmid: 34238613